Replay
Toggle
Menu
Platforms
Products
Team
News
Latest news
Filter By:
media
news
View All
Replay’s cell therapy product company Syena announces first patient dosed in Phase 1/2 study of TCR-NK cell therapy for multiple myeloma
Read More
11.03.2024
– NEWS
Replay and its engineered NK cell therapy company Syena announce exclusive licensing agreement with National Institutes of Health for TCRs targeting cancer neoantigens
Read More
18.12.2023
– NEWS
Replay’s oncology-focused product company Syena and Miltenyi Biotec enter into exclusive licensing and GMP manufacturing agreement for PRAME TCR-NK cell therapy based on CliniMACS Prodigy®
Read More
18.12.2023
– NEWS
In discussion with Chief Medical Officer, Arun Balakumaran: Exploring the potential of a TCR-NK cell therapy for sarcoma
Read More
21.11.2023
– NEWS
Replay announces partnership between product company Syena and JURA Bio to advance T cell receptor NK therapies in cancer
Read More
20.09.2023
– NEWS
Replay and MD Anderson announce FDA clearance of IND application for first-in-class T-Cell Receptor Natural Killer (TCR-NK) cell therapy for multiple myeloma
Read More
24.07.2023
– NEWS
Ask the Experts with Anthony Conway: What are “TCR-NKs”?
Read More
04.07.2023
– NEWS
Replay and MD Anderson announce FDA clearance of IND application for first-in-class T-Cell Receptor Natural Killer (TCR-NK) cell therapy for sarcoma
Read More
20.06.2023
– NEWS
Cristian Massacesi, M.D., Appointed to Replay Board of Directors
Read More
25.05.2023
– NEWS
Replay Appoints Arun Balakumaran M.D., Ph.D as Chief Medical Officer
Read More
18.05.2023
– NEWS
Rare Disease Day 2023: In conversation with Alex Silver
Read More
28.02.2023
– NEWS
KKR-backed Replay and MD Anderson form new product company Syena to pioneer first-in-class TCR-NK cell therapy
Read More
14.02.2023
– NEWS
Replay targets genetic brain disorders with new gene therapy company, Kaleibe, utilising big DNA HSV technology
Read More
14.12.2022
– NEWS
Replay receives $1.5 million grant for its hypoimmunogenic technology platform
Read More
28.11.2022
– NEWS
Replay launches big DNA HSV gene therapy company, Telaria, focused on rare skin diseases
Read More
21.11.2022
– NEWS
Replay launches its first HSV gene therapy company, Eudora, focused on retinal eye disease
Read More
31.10.2022
– NEWS
Replay establishes distinguished Scientific Advisory Board of genomic medicine and cell therapy experts
Read More
17.10.2022
– NEWS
Replay Launches with $55 Million Seed to Reprogram Biology by Writing and Delivering Big DNA
Read More
29.07.2022
– NEWS
Join Replay
Help us to author the future of genomic medicine
Open positions